Results · Apr-Jun 2026 · filed 11 Aug 2026
Beryl Drugs Q1 FY27 results
Sales grew 52% to ₹7.3 crore from ₹4.8 crore in Apr-Jun 2025.
Operating profit fell 26% to ₹0.38 crore, an operating margin of 5.2% (down 5.5 points from a year ago).
Net profit grew 946% to ₹0.22 crore from ₹0.02 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +42%, net profit −61%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 7.3 | 4.8 | +52% |
| Operating profit (EBITDA) | 0.4 | 0.5 | −26% |
| Operating margin | 5.2% | 10.6% | −5.5 pts |
| Net profit | 0.2 | 0.0 | +946% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 13 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 11 Aug 2026UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026
- 11 Aug 2026Board Meeting Outcome for OUTCOME OF BOARD MEETING
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.